Can-Fite BioPharma Ltd. (CANF), Friday announced that the Brazilian Patent Office has granted patent entitled Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction.
Following this, the granted patent provides intellectual-property protection in Brazil for the use of Can-Fites proprietary A3AR agonists in the treatment of sexual dysfunction.
The patent reflects the company's broader clinical and preclinical programs, which is expected to help create future partnering or commercialization opportunities in Latin America.
In the pre-market hours, CANF is trading at $0.24, down 1.94 percent on the New York Stock Exchange American.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.